Quantification of Potential Genotoxic Impurities in Amlodipine Besylate Using an Agilent GC/Q-TOF System

Importance of the Topic

Trace levels of genotoxic impurities in pharmaceutical products pose a significant risk to patient safety. Regulatory guidelines demand detection and quantitation of potential mutagens and carcinogens below defined thresholds. Ensuring reliable identification of sulfonate esters such as methylbenzene sulfonate and ethylbenzene sulfonate is critical to maintain product quality and compliance, especially in widely used drugs like amlodipine besylate.

Study Objectives and Overview

This work aims to develop and validate a selective GC/Q-TOF mass spectrometry method for simultaneous determination of methylbenzene sulfonate (MBS) and ethylbenzene sulfonate (EBS) in amlodipine besylate drug product. The study evaluates method performance in terms of sensitivity, precision, linearity, and structural elucidation via MS/MS. Application to degraded amlodipine samples demonstrates practical utility.

Methodology and Instrumentation

• Sample Preparation: Stock solutions of MBS and EBS (2,000 μg/mL) in acetonitrile; calibration standards from 5 to 5,000 ng/mL; degraded drug product extracted with acetonitrile/methanol (50:50) and spiked for recovery studies.
• Gas Chromatography: Agilent 7890A GC with multimode inlet, Agilent J&W DB-5ms column (30 m × 0.25 mm, 0.25 μm); helium carrier gas at 1.9 mL/min; injector program from 100 °C to 250 °C.
• Mass Spectrometry: Agilent 7200A Q-TOF operated in EI mode and MS/MS; mass range 50–600 Da; acquisition at 5 spectra/s in extended dynamic range; external calibration before each run.
• Software: Agilent MassHunter suite for acquisition, qualitative and quantitative analysis; MSC software for substructure assignment; NIST 2014 library search; ChemSpider integration for fragment matching.

Main Results and Discussion

• Selectivity and Resolution: Baseline separation of MBS and EBS within a 25 min run; selective extraction at ±10 ppm mass window minimized background interference.
• Sensitivity and Linearity: Limits of detection of 10 ng/mL for MBS and 20 ng/mL for EBS; LOQs of 20 ng/mL and 50 ng/mL, respectively; linear dynamic range up to 5,000 ng/mL with correlation coefficients >0.99 using 1/x weighting.
• Precision and Accuracy: Retention time RSDs <0.2 %; peak area RSDs <5 % across concentration levels (except LOQ for EBS at 8.4 %); recoveries between 100 ± 13 % at 0.05 % spike level.
• Structural Elucidation: MS/MS fragmentation patterns assigned with <4 ppm mass error; MSC software accurately matched substructures to confirm impurity identity.
• Application to Degraded Samples: Detected 344 ng/mL MBS and 3,687 ng/mL EBS in degraded amlodipine, demonstrating method sensitivity exceeding regulatory requirements by an order of magnitude.

Benefits and Practical Applications

This GC/Q-TOF assay offers high confidence in trace genotoxic impurity analysis without chemical derivatization, streamlines regulatory compliance workflows, and supports quality control in pharmaceutical manufacturing. The combined use of accurate mass data and MS/MS structural information ensures reliable identification and quantitation in complex matrices.

Future Trends and Opportunities

• Integration with automated data processing and AI-driven spectral interpretation to accelerate impurity profiling.
• Extension to other classes of genotoxic impurities and drug substances.
• Enhanced sensitivity through novel ionization techniques and higher resolution mass analyzers.
• Mobile and in-line monitoring for process analytical technology (PAT) applications in continuous manufacturing.

Conclusion

The described GC/Q-TOF method achieves sensitive, selective, and reproducible quantitation of MBS and EBS in amlodipine besylate, fulfilling regulatory demands for genotoxic impurity control. The approach leverages accurate mass and MS/MS data to confirm identities and offers a robust platform for routine pharmaceutical quality assurance.

References

1. Rao M. S. et al. Quantification of genotoxic impurities in amlodipine drug substance by LC-MS. Der Pharmacia Lettre, 2014, 6(3), 47–55.
2. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Ethyl Methane-Sulfonate, Vol. 7, 1974, p. 245.